S, COPD worsening was the most popular AE that exhibited the
S, COPD worsening was one of the most typical AE that exhibited the least incidence within the glycopyrronium group. Normally, AEs were properly balanced and the prices of occurrence of events for each glycopyrronium and tiotropium therapy arms have been similar to that of placebo. The only AEs (among the five most common AEs) observed in two of patients and that numerically improved with glycopyrronium had been nasopharyngitis and headache, which occurred with an incidence comparable to that of placebo and tiotropium.submit your manuscript | dovepress.comage 1,128 (51.74) 65 years 792 (36.33) 655 years 251 (11.51) 755 years 9 (0.41) 85 years sex Male 1,689 (77.48) Female 491 (22.52) race Caucasian 1,345 (61.70) Black 28 (1.28) asian 758 (34.77) Other 49 (two.25) variety of CCV risk components at baseline 0 217 (9.95) 1 571 (26.19) 2 570 (26.15) 822 (37.71) three COPD severity Mild 2 (0.09) Moderate 1,302 (59.72) extreme 868 (39.82) Quite serious 8 (0.37) steroid use none 948 (43.49) ICs 1,220 (55.96) OCs three (0.14) ICs and OCs 9 (0.41) Baseline diabetes 274 (12.57) conditionNote: Values are n . Abbreviations: CCV, cerebrovascular and cardiovascular; COPD, chronic obstructive pulmonary illness; glY, glycopyrronium; ICs, inhaled corticosteroids; n, sufferers randomized; OCs, oral corticosteroids; PBO, placebo; s-db, security database; TIO, tiotropium.International Journal of COPD 2015:DovepressDovepressComprehensive safety analysis of glycopyrroniumTable 4 Incidence of most common aes (per one hundred PTYs) in clinical research sorted by primary EGF Protein Gene ID system organ class and preferred term (ten events/100 PTYs for glY) (COPD core s-db)Primary system organ class, preferred term Individuals with 1 ae, quantity of aes/100 PTYs respiratory, thoracic, and mediastinal problems Total COPD worsening Cough Dyspnea Oropharyngeal pain sinus congestion Dysphonia nasal congestion epistaxis Infections and infestations Total nasopharyngitis Upper rTI decrease rTI Bronchitis sinusitis Urinary tract infection Viral upper rTI Influenza IL-1 beta, Mouse (CHO) Pneumonia Pharyngitis rhinitis Cellulitis Oral candidiasis gastroenteritis gastroenteritis viral rTI nervous system issues Total headache syncope Cardiac problems Total Atrial fibrillation angina pectoris eye disorders Total Cataract gastrointestinal problems Total Diarrhea Toothache Dyspepsia abdominal discomfort Vomiting Gastroesophageal reflux disease GLY 50 N=2,180 1,274 (58.44) 342.952 1,221 (107.233) 868 (76.231) 87 (7.641) 53 (4.655) 27 (two.371) 16 (1.405) 14 (1.230) 12 (1.054) 11 (0.966) 1,029 (90.371) 209 (18.355) 170 (14.930) 55 (four.830) 43 (3.776) 42 (three.689) 42 (3.689) 42 (3.689) 34 (two.986) 31 (two.723) 20 (1.756) 19 (1.669) 12 (1.054) 12 (1.054) 11 (0.966) ten (0.878) 10 (0.878) 205 (18.004) 82 (7.202) 14 (1.230) 104 (9.134) 15 (1.317) ten (0.878) 43 (3.776) ten (0.878) 263 (23.098) 29 (2.547) 16 (1.405) 15 (1.317) 13 (1.142) 13 (1.142) 12 (1.054) TIO 18 N=1,077 607 (56.36) 371.373 682 (127.659) 510 (95.464) 39 (7.300) 19 (three.556) 14 (2.621) 5 (0.936) 7 (1.310) 8 (1.497) five (0.936) 546 (102.202) 79 (14.788) 73 (13.664) 34 (6.364) 29 (five.428) 22 (four.118) 23 (four.305) 35 (six.551) 18 (three.369) 16 (two.995) 17 (3.182) 7 (1.310) six (1.123) 7 (1.310) three (0.562) four (0.749) five (0.936) 82 (15.349) 38 (7.113) 0 34 (6.364) 4 (0.749) five (0.936) 23 (four.305) 7 (1.310) 140 (26.206) ten (1.872) five (0.936) 6 (1.123) 8 (1.497) ten (1.872) 9 (1.685) PBO N=921 586 (63.63) 393.927 709 (139.508) 538 (105.860) 39 (7.674) 29 (five.706) 16 (three.148) two (0.394) 5 (0.984) eight (1.574) 2 (0.394) 537 (105.664) 93 (18.299) 100 (19.677) 28.